Unravelling IBD Therapeutics
Inflammatory bowel disease (IBD) is a complex condition with poorly understood mechanisms, and unknown causality. Despite its rapidly growing prevalence worldwide, IBD has a large, unmet therapeutic need, with a remarkably high failure rate of new drugs to enter the market. Increased understanding of the immunopathology of IBD has resulted in the development of novel therapies such as vedolizumab or ustekinumab, and the investigation of new agents including Janus kinase inhibitors, anti-mucosal vascular addressing cell adhesion molecule-1 agents, anti-interleukin-12/23 monoclonal antibody and sphingosine-1-phosphate receptor-1 selective agonists.
In this roundtable discussion, a panel of experts from pharma, biotech, and academia discuss challenges in the diagnosis and treatment of IBD, sharing their perspectives on current approaches towards the disease, and consider paradigm shifts happening within IBD drug development.
Key discussion points:
- The definition of IBD: one, a few, or many diseases?
- Current approaches against IBD, their successes and failures
- What we can expect from human phenotypic models in IBD drug development
- Taking steps towards personalized therapies, using biomarkers, genomics, transcriptomics, and phenomics
- The most promising novel therapeutic approaches
Meet the panel
Gijs van den Brink, M.D., Ph.D
Roche, Senior Vice President, Global Head of Immunology, Infectious Disease and Ophthalmology
Prof. dr. Willem Bemelman
AmsterdamUMC, Professor Gastroenterology Endocrinology Metabolism,
Professor, CCA - Cancer Treatment and Quality of Life, Professor, Surgery
Jos Joore, Ph.D
MIMETAS, co-founder and co-CEO
Watch the Roundtable Discussion by filling out the form below